More than 25 companies are actively developing over 30 drugs for myasthenia gravis, a chronic autoimmune disorder causing muscle weakness. Key therapies in late-stage trials include targeted biologics like Immunoglobulin G degraders and Complement factor B inhibitors, which promise improved treatment outcomes. Recent developments feature promising drugs such as Descartes-08 and Cemdisiran, with ongoing Phase III trials and regulatory progress in the US and EU. This expanding pipeline signals significant innovation and potential new treatment options for patients worldwide.
Novartis presented new clinical data at the EULAR 2026 Congress in London, showcasing results from its immunology portfolio targeting autoimmune diseases such as polymyalgia rheumatica, Sjögren’s disease, systemic lupus erythematosus, and systemic sc...
Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients, regardless of disease volume or presentation. The PSMA...
Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), regardless of disease volume or pre...
